

# Euroscreen announces Research Collaboration with Novartis

Brussels, Belgium June 30, 2009

Euroscreen SA a leader in G Protein Coupled Receptor (GPCR) science, today announced that it signed a Research Collaboration Agreement with Novartis to discover new targets for possible application in certain disease areas. Financial terms of the deal were not disclosed.

"We are pleased that Novartis decided to work with Euroscreen on selected orphan targets. This collaboration will allow Novartis to work with our target discovery team in multi-stage program", said Dr. Jean Combalbert, CEO of Euroscreen. "This type of collaboration aligns well with Euroscreen's strategy to partner its GPCR expertise while retaining in parallel its own discovery programs, particularly for small molecule applications."

## **About Euroscreen SA**

Euroscreen is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs. Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, EUROSCREEN is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.

Euroscreen pursues a dual business model strategy of combining its internal programs on high value targets (EUROSCREEN DRUG DISCOVERY) with its fully dedicated Business Unit (EUROSCREEN FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.

Euroscreen has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

Euroscreen has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Monogram Biosciences, Novartis and Pfizer. ([www.euroscreen.com](http://www.euroscreen.com))

For further information, please contact:

Euroscreen SA

Tél: +32 71 348 500

Email: [LicensingBD@euroscreen.com](mailto:LicensingBD@euroscreen.com)

Alfred Gray, Ph.D. and Vincent Lannoy, Ph.D.

Euroscreen Business Development